Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remibrutinib - Novartis

X
Drug Profile

Remibrutinib - Novartis

Alternative Names: LOU-064; LOU064-NXA; NVP-LOU064-NXA

Latest Information Update: 06 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Amines; Anti-inflammatories; Antiallergics; Antiasthmatics; Benzamides; Cyclopropanes; Ethers; Fluorobenzenes; Pyrimidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic urticaria; Multiple sclerosis
  • Phase II Hidradenitis suppurativa; Peanut hypersensitivity
  • Discontinued Asthma; Atopic dermatitis; Sjogren's syndrome

Most Recent Events

  • 31 May 2024 Updated pooled efficacy and adverse events data from the REMIX-1 and REMIX-2 trials in Chronic urticaria released by Novartis
  • 13 May 2024 Phase-III clinical trials in Chronic-urticaria (In children, In adolescents) (PO), before May 2024 (Novartis pipeline, May 2024)
  • 25 Apr 2024 Novartis completes a phase-III trial for Chronic-urticaria (In adults, In the elderly, Treatment-experienced) in Argentina, Canada, South Korea, Singapore, Spain, France, USA, Slovakia, Germany and Turkey (NCT05795153) (EudraCT2022-002838-13)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top